Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab versus teriflunomide in relapsing multiple sclerosis
MOH_2017-03-14_000012Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Ofatumumab arm with Teriflunomide arm (2 arms). Primary endpoint: Annualized relapse rate. Started Oct 2016; status: completed.
02
Drugs
ofatumumabteriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on MOH_2017-03-14_000012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-14_000012.